The pharmaceutical company now seeks DCGI (Drugs Controller General of India) nod to undertake clinical trials for monoclonal antibodies cocktail that can neutralise Covid infection. ZRC-3308 is a cocktail of 2 anti-SARS-CoV-2 monoclonal antibodies. ''Zydus Cadila today announced that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID 19. ZRC-3308 is a cocktail of two monoclonal antibodies targeting two unique epitopes on the spike protein of SARSCoV-2. The monoclonal antibodies of ZRC-3308 have been specifically designed to provide protection for a much longer period of time than the currently approved products.

Source: Mint May 27, 2021 03:11 UTC